Trial Profile
A Phase Ib/II Study of Yttrium-90 Radioembolization With Nivolumab for Treatment of Liver and Extra-hepatic Metastases From Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Yttrium-90 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as sponsor chose not to continue
- 13 Oct 2017 New trial record